Emerging issues on selection criteria of levodopa carbidopa infusion therapy: Considerations on outcome of 28 consecutive patients

Journal of Neural Transmission

Volumn 121, Issue 6, 2014, Pages 633-642

  Sensi, Mariachiara ^a   Preda, F ^a   Trevisani, L ^a   Contini, E ^a   Gragnaniello, D ^a   Capone, J G ^a   Sette, E ^a   Golfre Andreasi, N ^a   Tugnoli, V ^a   Tola, M R ^a   Quatrale, R ^b  

^a UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^b OSPEDALE DELL'ANGELO   (Italy)

Author keywords

Duodopa; Parkinson disease; Selection criteria

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; APOMORPHINE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CYANOCOBALAMIN; FOLIC ACID; LEVODOPA; NEUROLEPTIC AGENT; NOOTROPIC AGENT; ANTIPARKINSON AGENT; CARBIDOPA; CARBIDOPA, LEVODOPA DRUG COMBINATION; DRUG COMBINATION;

AGED; AGITATION; ARTICLE; CAREGIVER BURDEN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTINUOUS INFUSION OF INTRAJEJUNAL LEVODOPA CARBIDOPA GEL; DEMYELINATING DISEASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; DUODENUM ULCER; EVENING DOSAGE; FEMALE; FOLLOW UP; GAIT DISORDER; GEL; HALLUCINATION; HEART INFARCTION; HUMAN; INTRAJEJUNAL DRUG ADMINISTRATION; JEJUNOSTOMY TUBE; MALE; MALNUTRITION; MEDICAL DEVICE COMPLICATION; MENTAL DISEASE; MONOTHERAPY; MOOD DISORDER; OPEN STUDY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATIENT SAFETY; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PERITONITIS; PNEUMONIA; POLYNEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; QUALITY OF LIFE; SCORING SYSTEM; SEPSIS; SIDE EFFECT; UNIFIED PARKINSON DISEASE RATING SCALE; WEIGHT REDUCTION; CAREGIVER; DRUG ADMINISTRATION ROUTE; DRUG COMBINATION; DRUG DELIVERY SYSTEM; MENTAL HEALTH; MIDDLE AGED; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; PATIENT SELECTION; PSYCHOLOGY; QUESTIONNAIRE; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

AGED; AMANTADINE; ANTIPARKINSON AGENTS; APOMORPHINE; CARBIDOPA; CAREGIVERS; DRUG ADMINISTRATION ROUTES; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEVODOPA; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; PARKINSON DISEASE; PATIENT SELECTION; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 84901829696     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-013-1153-3     Document Type: Article

References (36)

1. Aarsland D, Andersen K, Larsen JP et al (2004) The rate of cognitive decline in Parkinson disease. Arch Neurol 61:1906-1911
2. Aarsland D, Brønnick K, Ehrt U (2007) Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 78:36-42. doi: 10.1136/jnnp.083113
3. Antonini A, Tolosa E (2009) Apomorphine and levodopa infusion therapies for advanced Parkinson disease: selection criteria and patient management. Expert Rev Neurother 9(6):859-867
4. Antonini A, Isaias IU, Canesi M et al (2007) Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 22:1145-1149
5. Antonini A, Mancini F, Canesi M et al (2008) Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease. Neurodegenerative Dis 5(3-4):244-246
6. Antonini A, Odin P, Lopiano L (2013) Effect and safety of duodenal levodopa infusion in advanced Parkinson's disease: a retrospective multicenter outcome assessment in patient routine care. J Neural Transm. doi: 10.1007/s00702-013-1026-9
7. Chaudhuri KR, Jose Rojo JM, Schapira AHV et al. (2013). A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need. PLOS ONE www.plosone.org 8 (2): e57221
8. DANMODIS, Danish Movement Disorder Society; SWEMODIS, Swedish Movement Disorder Society (2008) Duodopa: Scandinavian Consensus I. Treatment with levodopa/carbidopa gel (Duodopa) in patients with Parkinson's disease, Available at: http://info.parkinsonforbundet.se/wpcontent/uploads/duodopakonsensus-20081. pdf
9. Defer GL, Widner H, Rose- M et al (1999) Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord 14(4):572-584
10. Devos D (2009) Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 24(7):993-1000
11. Eggert K, Sckwrader C, Habner M et al (2008) Continuous jejunal levodopa infusion in patients with advanced Parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 31(3):151-166
12. Fasano A, Ricciardi L, Lena F et al (2012) Intrajejunal levodopa Infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life. Eur Rev Med Pharmacol Sci 16(1):79-89
13. Fernandez HH, Vanagunas B, Odin P et al (2013) Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: Interim results. Parkinsonism Relat Disord 19:339-345
14. Glozman JM, Bicheva KG, Fedorova NV (1998) Scale of quality of life of care-givers (SQLC). J Neurol 245(Suppl 1):S39-S41
15. Hindle V (2013) The practical management of cognitive impairment and psychosis in the older Parkinson's disease patient. J Neural Transm 120:649-653
16. Honig H, Antonini A, Martinez PP et al (2009) Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on non-motor symptoms and quality of life. Mov Disord 24(10):1468-1474
17. Johansson A, Nyholm D (2012) Continuous delivery of energy or l-dopa: identifying advantages and limitations of DBS and levodopa-carbidopa intestinal gel in the absence of head-to-head comparisons. Basal Ganglia 2:221-226
18. Kulisevsky J, Pagonabarraga J, Pascual-Sedano B et al (2008) Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia. Mov Disord 23(13):1889-1896
19. Kurth MC, Tetrud JW, Tanner CM et al (1993) Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with "on-off" fluctuations. Neurology 43:1698-1703
20. Nyholm D (2012) Duodopa treatment for advanced Parkinson's disease: a review of efficacy and safety. Parkinsonism Relat Disord ep 18(8):916-929
21. Nyholm D, Askmark H, Gomes-Trolin C et al (2003) Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 26(3):156-163
22. Nyholm D, Nilsson Remahl AIM, Dizdar N et al (2005) Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 64(2):216-223
23. Nyholm D, Lewander T, Johansson A et al (2008) Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 31(2):63-73
24. Nyholm D, Klangemo K, Johansson A (2012) Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease. Eur J Neurol. doi: 10.1111/j.1468-1331.201203679.x
25. Palhagen SE, Dizdar N, Hauge T et al (2012) Interim analysis of long-term intra-duodenal levodopa infusion in advanced Parkinson disease. Neurol Scand. doi: 10.1111/j.1600-0404.2012.01689
26. Puente V, De Fabregues O, Oliveras C et al (2010) Eighteen month study of continuous intra-duodenal levodopa infusion in patients with advanced Parkinson's disease: impact on control of fluctuations and quality of life. Parkinsonism Relat Disord 16(3):218-221
27. Reddy P, Martinez-Martin P, Rizos A, Martin A et al (2012) Intrajejunal levodopa versus conventional therapy in Parkinson disease: motor and non-motor effects. Clin Neuropharmacol 35(5):205-207
28. Robottom BJ, Gruber- Baldini AL, Anderson KE et al (2012) What determines resilience in patients with Parkinson's disease? Parkinsonism Relat Disord 18:174-177
29. Sánchez-Castañeda C, Jaume Campdelacreu J, Miró J et al (2010) Cognitive improvement after duodenal levodopa infusion in cognitively impaired Parkinson's disease patients. Prog Neuro Psychopharmacol Biol Psychiatry 34:250-251
30. Santos-Garcia D, Anon MJ, Fuster-Sanjurjo L, de la Fuente-Fernandez R (2012) Duodenal levodopa/carbidopa infusion therapy in patients with advanced Parkinson's disease leads to improvement in caregivers' stress and burden. Eur J Neurol 19(9):1261-1265
31. Schrag A, Hovris A, Morley D et al (2006) Caregiver-burden in Parkinson's disease is closely associated with psychiatric symptoms, falls and disability. Parkinsonism Relat Disord 12:35-41
32. Schuepbach WMM, Rau J, Knudsen K et al (2013) Neuro-stimulation for Parkinson's disease with early motor complications. New Engl J Med 368:610-622
33. Valldeoriola F, Puig-Junoy J, Puig-Peiró R, Workgroup of the SCOPE study (2013) Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study. J Med Econ 16(2):191-201. doi: 10.3111/13696998.2012.737392 (Epub 2012 Oct 29)
34. Volkmann J, Albanese A, Antonini A et al (2013) Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. J Neurol. doi: 10.1007/s00415-012-6798-6
35. Westin J, Nyholm D, Groth D et al (2006) Outcome prediction of enteral levodopa/carbidopa infusion in advanced Parkinson's disease. Parkinsonism Relat Disord 12:509-513
36. Zibetti M, Merola Z, Ricchi V et al (2013) Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study. J Neurol 260(1):105-114